CTIC 第二贴。

cschiaw · 发表于 23-7-2009 09:50 PM

Filled orders

Icons:

Buy |

Sell

Action

Ref No.

Exch

Exec. Code

Stock Name

Side

Pymt

Traded Curr

Sett. Curr

Avg. Fill price$

Order Qty

Match Qty

Status

Modified Date & Time

Via

101000650025

NMS

CTIC

CELL THERAPEUT

BUY

CASH

USD

1.36000

5,000

Filled

23-07-2009 21:30:48

CLT

premarket大跌 ! 趁机收多5粒 !

m.i.k.e · 发表于 29-7-2009 08:25 PM

赶快买票,飞机就要起飞了......

SEATTLE, July 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI"

(Nasdaq and MTA: CTIC) announced today that it was notified by the European Medicines Agency ("EMEA"

that pixantrone is eligible to be submitted for a Marketing Authorization Application ("MAA"

through the EMEA's centralized procedure. The centralized review process provides for a single coordinated review for approval of pharmaceutical products that is conducted by the EMEA on behalf of all European Union ("EU"

member states. The EMEA also designated pixantrone as a New Active Substance ("NAS"

; if approved, compounds designated as an NAS receive a 10-year market exclusivity period in EU member states. CTI will request a meeting with the EMEA to discuss the submission of the MAA for pixantrone to treat aggressive non-Hodgkin's lymphoma ("NHL"

in the EU member states.

CTI completed the submission of the New Drug Application ("NDA"

to the U.S. Food and Drug Administration ("FDA"

for pixantrone to treat relapsed or refractory, aggressive NHL in June 2009 and requested priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is currently available in Europe on a named-patient basis.

"Initiating the approval process for pixantrone in Europe is another significant milestone for CTI," said James A. Bianco, M.D., Chief Executive Officer of CTI. "Additionally, being granted SME status will support and reduce our cost of regulatory filings in Europe. More importantly, it will assist us in our submission of pixantrone for EU approval."

The SME program is an initiative by the EMEA that is dedicated to addressing the needs of small and medium size companies developing medicinal products in Europe. Companies granted SME status are able to seek assistance, information and training from dedicated EMEA personnel, particularly in support of Marketing Authorization Applications (MAA). In addition, SME status may result in reduced or deferred fees associated with marketing authorization applications, scientific advice and inspections. The EMEA also provides for translation of certain required documents. Restricted to companies based in the European Union, SME status has been granted to CTI Life Sciences Limited, a wholly-owned subsidiary of CTI, based in London, UK.

m.i.k.e · 发表于 29-7-2009 08:26 PM

卡...........................

m.i.k.e · 发表于 29-7-2009 08:26 PM

卡................

m.i.k.e · 发表于 29-7-2009 08:27 PM

卡................

m.i.k.e · 发表于 29-7-2009 08:27 PM

卡................

m.i.k.e · 发表于 29-7-2009 08:28 PM

卡................

m.i.k.e · 发表于 29-7-2009 08:29 PM

卡................

m.i.k.e · 发表于 29-7-2009 08:29 PM

卡................

m.i.k.e · 发表于 29-7-2009 08:30 PM

卡................

白面包 · 发表于 29-7-2009 08:35 PM

今天 pre market 上了 0.10。。昨天却掉了一些。。

白面包 · 发表于 29-7-2009 08:38 PM

Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe
- European Medicines Agency (EMEA) notifies CTI that pixantrone is eligible for centralized procedure in European Union - CTI granted Small and Medium Enterprise (SME) status by the European Union and EMEA - will provide additional development assistance and reduce cost for regulatory filing

原来是这个消息